## **Supplementary Online Content**

Kelly KR, Jost RM, Dao L, Beauchamp CL, Leffler JN, Birch EE. Binocular iPad game vs patching for treatment of amblyopia in children: a randomized clinical trial. *JAMA Ophthalmol*. Published online November 10, 2016. doi:10.1001/jamaophthalmol.2016.4224

eTable 1. Inclusion and Exclusion Criteria

eTable 2. Baseline Characteristics

This supplementary material has been provided by the authors to give readers additional information about their work.

© 2016 American Medical Association. All rights reserved.

eTable 1. Inclusion and Exclusion Criteria

Inclusion criteria
Age 4-10 years
0.3-0.8 logMAR amblyopic eye BCVA
0.1 logMAR or better fellow eye BCVA (0.2 logMAR or better for 4 year-olds)
≥3 lines interocular difference
≥8 weeks in glasses (if needed) OR no change in BCVA with glasses at 2 visits
separated by 4-6 weeks
Amblyopia due to strabismus, anisometropia, or both meeting the following
criteria:
Strabismus: acquired esotropia with or without a history of alignment surgery
Anisometropia: Hyperopic and/or astigmatic anisometropia ≥ 1.0 diopter
spherical equivalent or astigmatism with or without microtropia
Combined mechanism: acquired esotropia and anisometropia with or without
a history of alignment surgery
Good ocular alignment (no strabismus >4 PD)
Demonstrate ability to understand and play the binocular game at enrollment
Exclusion criteria
Prematurity >8 weeks
Coexisting ocular or systemic disease
Developmental delay
Myopic anisometropia
Prior binocular amblyopia treatment

eTable 2. Baseline Characteristics

	Total (N=28)	Binocular game (n=14)	Patching (n=14)
Sex: F	7	3	4
Age, years			
4–6	17	9	8
7–10	11	5	6
Mean±SD, years	6.78±1.44	6.60±1.39	6.95±1.51
Prior amblyopia treatment			
None	8	4	4
Patching	12	7	5
Atropine	1	1	0
Patching + atropine	7	2	5
Weeks in glasses			
8–13	3	2	1
>13-26	3	2	1
>26	22	10	12
Cause of amblyopia			
Strabismus	9	4	5
Anisometropia	14	7	7
Combined	5	3	2
AE BCVA, logMAR (Snellen equivalent)			
0.3-0.6 (20/40-20/80)	23	12	11
0.7–0.8 (20/100– 20/125)	5	2	3
Mean±SD, logMAR	0.48±0.14	0.46±0.14	0.50±0.15
	(~20/63±1.4 lines)	(~20/63±1.4 lines)	(20/63±1.5 lines)
FE BCVA, logMAR (Snellen equivalent)			
-0.1 (20/16)	7	4	3
0.0 (20/20)	9	4	5
0.1 (20/25)	12	6	6
Mean±SD, logMAR	0.02±0.08	0.01±0.09	0.02±0.08

© 2016 American Medical Association. All rights reserved.

$(\sim 20/20 + 0.8 \text{ lines})$	$(\sim 20/20 \pm 0.9 \text{ lines})$	$(\sim 20/20 + 0.8 \text{ lines})$
( 20/20±0.0 inics)	( 20/20±0.5 inies)	( 20/20±0.0 IIICs)